Hørsholm, Denmark – January 13, 2025
AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market. Under this collaboration, Cevidra will serve as the local pharmaceutical Exploitant and distribution partner in France, leveraging its expertise to support AFYX in the introduction of new therapies to healthcare professionals.
About Cevidra and AFYX pharmaceutical companies seeking to commercialize medicines through Early Access Programs (AAC, AAP) or Licensed Products (MA).
Claus Møller-San Pedro
CEO & Founder
About Cevidra and AFYX
As a one-stop company, Cevidra offers fully integrated solutions, including price and reimbursement, local pharmacovigilance, CRO services for data collection, distribution, and tailored promotional activities. Cevidra, with its Exploitant status, is the gateway to the French market for AFYX:
At AFYX – Reversed Innovation is our core value. As a leader in the biopharmaceutical industry, reversed innovation aligns with our broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition. For more information: https://afyxtx.com
For more information: Please contact:
Loïc Fiévet; l.fievet@cevidra.com; +33493705831